<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002963</url>
  </required_header>
  <id_info>
    <org_study_id>DS 92-42</org_study_id>
    <secondary_id>RPCI-DS-92-42</secondary_id>
    <secondary_id>NCI-V97-1191</secondary_id>
    <nct_id>NCT00002963</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy in Treating Patients With Skin Cancer</brief_title>
  <official_title>Cutaneous Absorption and Intralesional Penetration of Topical Amino-Levulinic Acid in Basal Cell Carcinoma and Squamous Cell Carcinoma as Measured by In Situ Fluorescence and Intensified Video Fluorescence Microscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to&#xD;
      light to kill tumor cells. Photodynamic therapy using aminolevulinic acid cream may be&#xD;
      effective in treating patients with skin cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well photodynamic therapy works in&#xD;
      treating patients with skin cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Characterize the penetration of topically applied aminolevulinic acid (ALA) into the&#xD;
           lesions of patients with primary basal cell and squamous cell carcinomas.&#xD;
&#xD;
        -  Quantitate the depth of fluorescence achievable with varying application periods of ALA&#xD;
           in these patients.&#xD;
&#xD;
        -  Compare the results of tissue fluorescence with surface fluorescence measurements in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to lesion type&#xD;
      (superficial basal cell carcinoma (BCC) vs nodular BCC vs squamous cell carcinoma). Patients&#xD;
      within each group are randomized to receive one of two application times: 4-5 or 20-24 hours&#xD;
      in duration.&#xD;
&#xD;
      Aminolevulinic acid is topically applied either in a cream mixture or an alcohol base and an&#xD;
      occlusive dressing placed over the lesion. After the randomized treatment duration has&#xD;
      expired, the dressing is removed and quantitative protoporphyrin IX fluorescence measurements&#xD;
      from the tumor and surrounding skin are mapped using a fluorometer. Routine surgical excision&#xD;
      is then performed on the carcinoma.&#xD;
&#xD;
      Patients return after one to two weeks for a follow-up examination and suture removal.&#xD;
&#xD;
      PROJECTED ACCRUAL: 54 patients will be accrued within 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1993</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Depth of penetration of aminolevulinic acid as measured by the accumulation of protoporphyrin IX</measure>
  </primary_outcome>
  <condition>Non-melanomatous Skin Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aminolevulinic acid hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven basal cell carcinoma or squamous cell carcinoma&#xD;
&#xD;
          -  Candidate for complete surgical excision&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No inflammation or infection of treated area&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Biopsy at least 2 weeks prior to surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan R. Oseroff, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <keyword>basal cell carcinoma of the skin</keyword>
  <keyword>squamous cell carcinoma of the skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

